Press coverage about Adaptimmune Therapeutics (NASDAQ:ADAP) has been trending somewhat positive on Monday, Accern Sentiment reports. The research group ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Adaptimmune Therapeutics earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 46.3168580549171 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
A number of brokerages have issued reports on ADAP. ValuEngine downgraded shares of Adaptimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday. SunTrust Banks reissued a “buy” rating and set a $10.00 target price on shares of Adaptimmune Therapeutics in a research report on Friday, November 10th. Zacks Investment Research downgraded shares of Adaptimmune Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 10th. TheStreet raised shares of Adaptimmune Therapeutics from a “d” rating to a “c” rating in a research report on Thursday, November 2nd. Finally, Leerink Swann reissued an “outperform” rating and set a $15.00 target price on shares of Adaptimmune Therapeutics in a research report on Friday, September 8th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $11.58.
Adaptimmune Therapeutics (NASDAQ ADAP) traded down $0.17 during midday trading on Monday, reaching $7.93. 146,978 shares of the company’s stock traded hands, compared to its average volume of 256,857. Adaptimmune Therapeutics has a fifty-two week low of $3.76 and a fifty-two week high of $9.29.
COPYRIGHT VIOLATION WARNING: This article was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The correct version of this article can be read at https://www.dispatchtribunal.com/2017/12/04/adaptimmune-therapeutics-plc-adap-earns-coverage-optimism-score-of-0-14.html.
About Adaptimmune Therapeutics
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.
Receive News & Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.